Executive Summary
Lipid nanoparticles have moved from a specialized delivery technology into an established FDA approval platform for nucleic acid medicines. The US record now includes an RNA interference therapeutic and five messenger RNA vaccines spanning COVID-19, respiratory syncytial virus, and influenza.
FDA review history makes the delivery system a central product quality issue. The recurring CMC themes are payload release or expression, encapsulation, particle size and distribution, lipid identity and impurities, sterile processing, stability, and comparability across process, scale, and site changes.
The next regulatory test is in vivo gene editing. An LNP delivered CRISPR therapy is under FDA BLA review, while other LNP base editing programs have reached pivotal or early clinical development.
What Lipid Nanoparticles Are
Lipid nanoparticles (LNPs) are nanoscale lipid assemblies used to encapsulate and deliver ribonucleic acid (RNA) payloads. In the approved products covered here, the payload is messenger RNA (mRNA) or small interfering RNA (siRNA). Ionizable or cationic lipids support nucleic acid association and intracellular delivery, while helper phospholipids, cholesterol, and polyethylene glycol (PEG) lipids contribute to particle structure and formulation behavior. 123
FDA's public assessments show controls for LNP size and polydispersity, RNA encapsulation, RNA content and integrity, lipid identity and content, lipid impurities, and functional RNA expression or release. These attributes place the LNP directly inside the product quality control strategy. 425
This article uses LNP to describe nucleic acid delivery systems based on lipid nanoparticles or lipid complexes that perform this encapsulation and delivery function. Conventional liposomal small molecule products are outside this scope. 21
The FDA Approved US Product Set
As of September 30, 2026, the FDA approved US set within this scope consists of one siRNA therapeutic and five mRNA vaccines. The sequence begins with patisiran in 2018, followed by the first full approval of an mRNA vaccine for coronavirus disease 2019 (COVID-19) in 2021 and later expansion into respiratory syncytial virus and seasonal influenza vaccination. 67891011
| FDA approved product | Initial US approval | Payload and LNP system | Current FDA indicated use |
|---|---|---|---|
| Onpattro | August 10, 2018 | Patisiran siRNA formulated as a lipid complex for hepatocyte delivery; includes DLin-MC3-DMA, PEG2000-C-DMG, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and cholesterol. | Polyneuropathy of hereditary transthyretin mediated amyloidosis in adults. |
| Comirnaty | August 23, 2021 | mRNA COVID-19 vaccine in an LNP containing ALC-0315, ALC-0159, DSPC, and cholesterol. | Prevention of COVID-19 in persons 65 years and older, or ages 5 through 64 years with at least one underlying condition associated with high risk for severe outcomes. |
| Spikevax | January 31, 2022 | mRNA COVID-19 vaccine using SM-102, cholesterol, DSPC, and PEG2000-DMG. | Prevention of COVID-19 in persons 65 years and older, or ages 6 months through 64 years with at least one underlying condition associated with high risk for severe outcomes. |
| MRESVIA | May 31, 2024 | 50 micrograms of mRNA encoding respiratory syncytial virus prefusion F protein in an LNP composed of SM-102, PEG2000-DMG, cholesterol, and DSPC. | Prevention of lower respiratory tract disease caused by respiratory syncytial virus in persons 60 years and older and adults ages 18 through 59 years at increased risk. |
| MNEXSPIKE | May 30, 2025 | 10 micrograms of mRNA-1283 per dose in an LNP using SM-102, cholesterol, DSPC, and mPEG2000-DMG. | Prevention of COVID-19 in persons 65 years and older, or ages 12 through 64 years with at least one underlying condition associated with high risk for severe outcomes. |
| MFLUSIVA | August 5, 2026 | Trivalent mRNA influenza vaccine containing three monovalent LNP components, 37.5 micrograms total mRNA per dose, using SM-102, PEG2000-DMG, DSPC, and cholesterol. | Prevention of influenza disease in persons 50 years and older. FDA used traditional approval for ages 50 through 64 years and accelerated approval for ages 65 years and older. |
Key Suppliers and Technology Providers
Public disclosures identify several companies with direct roles in LNP technology or lipid supply for US approved products. The commercial vendor map is incomplete in public materials, so product specific supplier attribution is limited to disclosed relationships. 1121314
| Company | Publicly documented role | Approved product connection |
|---|---|---|
| Acuitas Therapeutics | Proprietary LNP delivery technology | Acuitas identifies its technology as enabling Onpattro and Comirnaty. |
| Croda / Avanti Polar Lipids | Supply of four component excipients under an agreement with Pfizer | Pfizer and BioNTech COVID-19 vaccine program associated with Comirnaty. |
| Evonik | Commercial production of two specialty lipids for BioNTech | Pfizer and BioNTech COVID-19 vaccine program associated with Comirnaty. |
| CordenPharma | Large scale manufacture of Moderna lipid excipients, including capacity in Colorado | Moderna mRNA-1273 program, subsequently approved as Spikevax. |
| Other product specific commercial suppliers | Public attribution is incomplete in the cited materials | FDA reviews define composition and manufacturing controls for MRESVIA, MNEXSPIKE, MFLUSIVA, and Onpattro, but the cited sources do not provide a complete named vendor map for every lipid component. |
CMC Challenges Visible in FDA Review
Chemistry, Manufacturing, and Controls (CMC) review of LNP products has to establish control over the nucleic acid, lipid components, assembled particle, and finished sterile product. The most explicit public FDA challenges appear in the Onpattro quality assessment. FDA found robustness concerns with the siRNA in vitro release method, accepted it on an interim basis, and obtained a postmarketing commitment for a new validated and robust method within 12 months of the action date. 2
FDA also documented that the full maximum Onpattro dose volume could not pass through a single 0.2 micrometer polyethersulfone filter. The applicant evaluated larger pore sizes, demonstrated comparable quality, and FDA accepted labeling that specified a sterile 0.45 micrometer filter for dose preparation. The same review identified the two novel synthetic lipids, manufacturing and sterile fill complexity, stability, leachables, and potential glass delamination as critical issues that were ultimately addressed. 2
Later mRNA reviews show a broader platform control strategy. Comirnaty release testing included LNP size and polydispersity, RNA encapsulation and content, lipid identity and content, and functional RNA expression. Spikevax and MNEXSPIKE relied on comparability across process versions, scales, sites, and commercial qualification lots. MFLUSIVA bridged clinical LNP-100 to commercial LNP-102 using release testing, extended characterization, stability, and nonclinical immunogenicity, while FDA also evaluated degradation rates that included mRNA purity and total lipid impurities. 415165
| CMC issue | FDA precedent | Development implication |
|---|---|---|
| Functional release or expression | Onpattro required a new validated siRNA release method after FDA identified robustness concerns; Comirnaty included in vitro RNA expression in its control strategy. | Establish a functional assay strategy early enough for validation, specification setting, stability, and lifecycle use. |
| Particle attributes | Comirnaty controlled LNP size and polydispersity. | Define particle measurements for release, stability, and comparability. |
| Encapsulation and RNA quality | FDA reviews control RNA encapsulation, content, integrity, or purity. | Link payload quality and encapsulation to process parameters and degradation pathways. |
| Lipid identity and impurities | FDA reviews include individual lipid identity and content; MFLUSIVA includes lipid impurity controls; Onpattro introduced two novel synthetic lipid excipients. | Build raw material, impurity, analytical, and stability strategies for each functional lipid. |
| Sterile filtration | Onpattro required a clinically workable filter specification after the maximum dose could not pass through a single 0.2 micrometer filter. | Test filtration at clinically relevant concentration and volume and confirm particle quality after filtration. |
| Comparability | Spikevax, MNEXSPIKE, and MFLUSIVA used analytical, process, stability, and qualification evidence to bridge manufacturing changes. | Plan comparability around predefined critical quality attributes before scale, site, or process transitions. |
| Stability | MFLUSIVA assessed degradation behavior including mRNA purity and total lipid impurities. | Use stability indicating methods for both payload and delivery system. |
The Development Landscape
The development landscape is moving from RNA silencing and vaccination into in vivo genome editing. These programs can use LNPs to deliver an editor mRNA plus a guide RNA, adding component identity, stoichiometry, delivery, functional activity, and editing performance to the established LNP CMC framework. 171819
Lonvoguran ziclumeran, or lonvo-z, is the near term regulatory test. Intellia describes a nonviral LNP system delivering CRISPR associated protein 9 (Cas9) mRNA and a KLKB1 specific guide RNA to hepatocytes. FDA accepted its Biologics License Application (BLA) and granted Priority Review with a target action date of March 10, 2027. Intellia participated in FDA's CMC Development and Readiness Pilot. 172021
Beam reported the first patient dosed in the global pivotal cohort for the LNP base editing program BEAM-302 in August 2026, and FDA cleared the Investigational New Drug (IND) application for the LNP based BEAM-304 program in June 2026. Verve's VERVE-102 uses an internally developed targeted LNP in a Phase 1b study. Acuitas and Beam also describe work on delivery beyond established liver and intramuscular applications, including immune cells, hematopoietic stem cells, lung, and ocular delivery. 18222319124
| Program | LNP role | Status as of September 30, 2026 |
|---|---|---|
| Lonvo-z, Intellia | Nonviral LNP delivers Cas9 mRNA and KLKB1 specific guide RNA to hepatocytes | BLA accepted with Priority Review; target action date March 10, 2027. |
| Nex-z, Intellia | In vivo CRISPR editing delivered with Intellia LNP technology | Late stage clinical development for transthyretin amyloidosis. |
| BEAM-302, Beam | Liver targeted LNP formulation of base editing reagents for alpha-1 antitrypsin deficiency | Global pivotal cohort initiated in 2026. |
| BEAM-304, Beam | Liver targeted LNP formulation of base editing reagents for phenylketonuria | FDA cleared the IND in June 2026. |
| VERVE-102, Verve | In vivo base editing using an internally developed targeted LNP | Phase 1b Heart-2 study. |
| Extrahepatic LNP programs | Targeting immune cells, hematopoietic stem cells, lung, eye, and other tissues | Development stage varies; no FDA approval precedent identified in the cited sources. |
Conclusion
FDA approved LNP products now span siRNA therapy and mRNA vaccines across several infectious disease indications. Their regulatory histories establish a practical CMC foundation around payload quality, lipid control, particle attributes, encapsulation, functional assays, sterile processing, stability, and comparability.
In vivo gene editing is the next major regulatory test because the LNP delivers multiple functional components for a permanent genomic intervention. The current record supports increasingly platform based development, with product specific evidence required when formulation, payload, process, site, scale, or target tissue changes.